UNSPSC 51411505: Stevaladil

This classification denotes a vasodilating agent with the molecular formula C27H45NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FW24343731, chemically known as 3beta-(dimethylamino)-5alpha-pregnane-18,20alpha-diol diacetate (ester) but generally known as stevaladil, which bears US NIH Compound Identifier 3083966. European Medicines Agency schedules Stevaladil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10647MIG.

UNSPSC 51411505 Stevaladil, a Commodity code, covers pharmaceutical products state and local governments procure for emergency medical services, health agencies, and institutional healthcare programs. Recent solicitations show state and local buyers purchasing specific advanced life support medications (epinephrine, labetalol, adenosine, diltiazem), generic multi-source pharmaceuticals across therapeutic categories, and over-the-counter products through both direct supply and wholesale distribution channels. Issuing bodies include municipal fire rescue services, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The code sees activity from city procurement offices managing emergency medical supplies, state health departments managing pharmacy benefit programs, and cooperative purchasing entities administering regional contracts for multiple member agencies.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the most visible opportunities appearing in multistate cooperative purchasing frameworks that serve multiple jurisdictions simultaneously. The City of Tampa's Purchasing Department solicited advanced life support medications via sealed bid (IFB No. 26P00188, response due April 8, 2026) for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year initial term plus optional renewals, including a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response due April 3, 2026) exploring direct-to-manufacturer prescription programs to inform future procurement strategy. All recent solicitations require FDA compliance, Good Manufacturing Practice certification, Drug Supply Chain Security Act adherence, and expiration-date warranties of nine months to one year from delivery.